Caxton Associates LLP Arvinas, Inc. Transaction History
Caxton Associates LLP
- $3.94 Trillion
- Q2 2025
A detailed history of Caxton Associates LLP transactions in Arvinas, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 298,062 shares of ARVN stock, worth $2.86 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
298,062Holding current value
$2.86 Million% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding ARVN
# of Institutions
245Shares Held
68.3MCall Options Held
2.99MPut Options Held
534K-
Vanguard Group Inc Valley Forge, PA9.39MShares$90.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$60.1 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.67MShares$35.3 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA3.3MShares$31.7 Million3.14% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.15MShares$20.7 Million0.01% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $511M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...